Residency · Residency · Ophthalmology
The Diabetic Eye Beyond Retinopathy: Corneal, Lens, and Neuro-Ophthalmic Manifestations
Introduction
While diabetic retinopathy dominates clinical attention, diabetes mellitus affects virtually every structure of the eye. Corneal neuropathy, neurotrophic keratopathy, accelerated cataract formation, refractive fluctuations, cranial nerve palsies, and optic neuropathy are all well-recognized manifestations that contribute to visual morbidity. A comprehensive understanding of these non-retinal complications ensures that they are not overlooked during management of the diabetic patient.
Corneal Manifestations
Diabetic Keratopathy
Affects 47-64% of diabetic patients to some degree. Corneal epithelial fragility: basement membrane abnormalities with weakened epithelial adhesion. Recurrent corneal erosions and persistent epithelial defects. Delayed wound healing after corneal surgery or trauma. Important consideration during vitreoretinal surgery (epithelial defects from contact lens use, prolonged procedures)
Diabetic Corneal Neuropathy
Loss of corneal nerve fibers documented by corneal confocal microscopy (CCM). Reduced corneal sensitivity (measured by Cochet-Bonnet esthesiometry) Correlates with severity of peripheral diabetic neuropathy. CCM is being studied as a surrogate biomarker for systemic diabetic neuropathy. Decreased nerve fiber density, branching, and length on CCM.
Neurotrophic Keratopathy
Neurotrophic corneal ulcer: painless, oval, paracentral epithelial defect with smooth rolled edges. Stages (Mackie classification): Stage 1: punctate epitheliopathy, corneal edema. Stage 2: persistent epithelial defect with smooth edges. Stage 3: corneal ulceration with stromal lysis and possible perforation. Management: preservative-free lubricants, bandage contact lens, tarsorrhaphy, amniotic membrane.
Cenegermin (Oxervate): recombinant human nerve growth factor (NGF) drops; FDA-approved for neurotrophic keratitis. Autologous serum tears (20% concentration)
Corneal Endothelial Changes
Decreased endothelial cell density and increased pleomorphism/polymegethism. Greater susceptibility to corneal edema after intraocular surgery. Important in cataract surgery planning; endothelial cell count assessment.
Dry Eye Disease
Increased prevalence in diabetics (up to 54%) Reduced tear production (aqueous deficiency), meibomian gland dysfunction. Contributes to surface irregularity and visual symptoms.
Lens Manifestations
Diabetic Cataract
True diabetic cataract (snowflake cataract): bilateral, rapidly progressive, white subcapsular opacities. Rare; typically occurs in young type 1 diabetics with poorly controlled glucose. Related to sorbitol accumulation via the aldose reductase pathway (polyol pathway) Sorbitol accumulation causes osmotic swelling and disruption of lens fiber architecture. Accelerated age-related cataract: more common; posterior subcapsular and cortical cataracts develop earlier in diabetics. Diabetics undergo cataract surgery more frequently and at younger ages.
Refractive Changes
Transient refractive shifts: acute hyperglycemia causes myopic shift; correction of hyperglycemia causes hyperopic shift. Mechanism: osmotic changes in the lens from sorbitol accumulation alter lens thickness and refractive index. Advise patients to defer refraction for new glasses until glucose is stable for 2-4 weeks. Can cause significant visual complaints and confusion if not recognized.
Surgical Considerations in Diabetic Cataract Surgery
Higher risk of postoperative complications: CME, inflammation, posterior capsule opacification. Preoperative optimization: treat any diabetic retinopathy (anti-VEGF, PRP) before or concurrent with cataract surgery. Intracameral or perioperative anti-VEGF may reduce postoperative macular edema. More aggressive postoperative anti-inflammatory regimen (topical NSAIDs + steroids) Careful endothelial assessment preoperatively.
Iris and Pupil
Diabetic Autonomic Neuropathy
Small, poorly dilating pupil: autonomic neuropathy affecting the iris dilator muscle. Makes fundoscopic examination and vitreoretinal surgery more challenging. May require intracameral phenylephrine, iris hooks, or pupil expansion devices. Reduced mydriatic response to pharmacologic dilation.
Rubeosis Iridis
Neovascularization of the iris (NVI): occurs in proliferative diabetic retinopathy. Precursor to neovascular glaucoma. Requires urgent treatment: intravitreal anti-VEGF followed by panretinal photocoagulation. Not further discussed here (covered in diabetic retinopathy lecture)
Neuro-Ophthalmic Manifestations
Diabetic Cranial Neuropathy
Third nerve palsy (CN III): most commonly affected cranial nerve in diabetes. Characteristically pupil-sparing (unlike compressive third nerve palsy from aneurysm) Mechanism: microvascular ischemia of the nerve trunk (vasa nervorum); spares peripheral pupillary fibers. Presents with ptosis, restricted adduction, elevation, and depression; diplopia. Spontaneous recovery expected within 2-3 months. Must rule out posterior communicating artery aneurysm if pupil is involved (imaging mandatory)
Sixth nerve palsy (CN VI): second most common; lateral rectus weakness causing esotropia and horizontal diplopia. Microvascular ischemia; resolves in 2-3 months. Fourth nerve palsy (CN IV): less common; vertical diplopia, head tilt. Multiple cranial neuropathies: consider alternative etiologies (cavernous sinus thrombosis, malignancy, GCA)
| Diabetic Ocular Manifestation | Structure Affected | Key Clinical Feature | Management |
|---|---|---|---|
| Diabetic keratopathy | Corneal epithelium | Epithelial fragility; delayed healing | Lubrication; avoid trauma |
| Neurotrophic keratopathy | Corneal nerves | Painless persistent epithelial defect | Cenegermin (NGF); AMT; tarsorrhaphy |
| Snowflake cataract | Lens | Bilateral white subcapsular opacities (type 1 DM) | Cataract surgery |
| Refractive shifts | Lens | Myopic/hyperopic shift with glucose changes | Defer refraction until glucose stable 2-4 weeks |
| CN III palsy (pupil-sparing) | Oculomotor nerve | Ptosis, diplopia; pupil spared | Observation; resolves in 2-3 months |
| CN VI palsy | Abducens nerve | Esotropia; horizontal diplopia | Observation; resolves in 2-3 months |
| Diabetic papillopathy | Optic disc | Mild disc edema; mildly reduced VA | Self-limiting; monitor |
| NAION | Optic nerve | Sudden painless vision loss; altitudinal defect | Risk factor modification; no proven treatment |
Diabetic Papillopathy
Mild optic disc edema in patients with diabetes, often bilateral. Visual acuity often mildly affected or normal. Visual field: enlarged blind spot. Mechanism: possibly microvascular insufficiency at the optic nerve head. Self-limiting; resolves over weeks to months. Must distinguish from anterior ischemic optic neuropathy (AION), papilledema, and optic neuritis.
Does not require treatment; monitor for resolution.
Diabetic Optic Neuropathy
Diabetes is a major risk factor for non-arteritic anterior ischemic optic neuropathy (NAION). Sudden, painless, monocular vision loss with altitudinal visual field defect and disc edema. Small cup-to-disc ratio ("disc at risk") in the fellow eye. No proven treatment for NAION; risk factor modification (glucose, hypertension, sleep apnea screening)
Other Neuro-Ophthalmic Associations
Mucormycosis (rhinocerebral): life-threatening invasive fungal infection in uncontrolled diabetes (especially diabetic ketoacidosis) Orbital apex syndrome: proptosis, ophthalmoplegia, vision loss. Emergency management: systemic amphotericin B, surgical debridement, glucose control. Increased risk of cerebrovascular disease affecting visual pathways (homonymous hemianopia from stroke)
Glaucoma in Diabetes
Primary open-angle glaucoma: increased prevalence in diabetics (contested but supported by large epidemiologic studies) Neovascular glaucoma: most feared; secondary to proliferative retinopathy. Steroid-induced glaucoma: higher risk due to frequent corticosteroid use for DME. Consider IOP effects when prescribing intravitreal or periocular steroids.
Comprehensive Diabetic Eye Examination
Visual acuity with refraction (defer new prescription during glucose instability) Pupillary examination: RAPD, pupil size and reactivity. Motility assessment: rule out cranial nerve palsies. Slit-lamp examination: corneal epitheliopathy, cataract type, NVI, anterior chamber inflammation. IOP measurement. Dilated fundus examination with retinopathy grading.
OCT: macular thickness, vitreoretinal interface. Consider corneal confocal microscopy in research settings.
Key Clinical Pearls
Refractive shifts in diabetic patients are caused by osmotic changes in the lens; defer new spectacle prescriptions until blood glucose has been stable for at least 2-4 weeks. A pupil-sparing third nerve palsy in a diabetic patient suggests microvascular ischemia rather than compression, but imaging is mandatory if any pupil involvement is present. Diabetic corneal neuropathy causes neurotrophic keratopathy and impaired wound healing; corneal confocal microscopy is emerging as a biomarker for systemic diabetic neuropathy. Cenegermin (recombinant NGF) is an FDA-approved treatment option for neurotrophic keratitis in diabetic patients.
References
- Ljubimov AV. Diabetic complications in the cornea. Vision Res. 2017;139:138-152.
- Calvo-Maroto AM, Perez-Cambrodí RJ, Albarrán-Diego C, et al. Optical quality of the diabetic eye: a review. Eye (Lond). 2014;28(11):1271-1280.
- Watanabe K, Hagura R, Akanuma Y, et al. Characteristics of cranial nerve palsies in diabetic patients. Diabetes Res Clin Pract. 1990;10(1):19-27.
- Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol. 2014;8:571-579.